(State or other jurisdiction of incorporation) | (Commission File Number) | (IRS Employer Identification No.) | ||||||||||||
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) | |||||
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) | |||||
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) | |||||
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Title of each class | Trading Symbol(s) | Name of each exchange on which registered | ||||||
None |
Bellicum Pharmaceuticals, Inc. | |||||||||||||||||
Dated: August 21, 2023 | By: | /s/ Richard A. Fair | |||||||||||||||
Richard A. Fair | |||||||||||||||||
Principal Executive and Financial Officer | |||||||||||||||||
Cover |
Aug. 21, 2023 |
---|---|
Entity Addresses [Line Items] | |
Document Type | 8-K |
Document Period End Date | Aug. 21, 2023 |
Entity Registrant Name | Bellicum Pharmaceuticals, Inc. |
Entity Incorporation, State or Country Code | DE |
Entity File Number | 001-36783 |
Entity Tax Identification Number | 20-1450200 |
Entity Address, Address Line One | 3730 Kirby Drive |
Entity Address, Address Line Two | Ste. 1200 |
Entity Address, City or Town | Houston |
Entity Address, State or Province | TX |
Entity Address, Postal Zip Code | 77098 |
City Area Code | 281 |
Local Phone Number | 454-3424 |
Written Communications | false |
Soliciting Material | false |
Pre-commencement Tender Offer | false |
Pre-commencement Issuer Tender Offer | false |
Title of 12(b) Security | Common Stock, par value $0.01 per share |
Trading Symbol | BLCM |
Entity Emerging Growth Company | false |
Entity Central Index Key | 0001358403 |
Amendment Flag | false |
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end
*B !$LPTZ63=M)/9-,DD[K2[G1T-/FU.)=)#T;'][Q>D))NT
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MYXCR+[ =!LJW $0@@"_O5O+LS0O/6].19POU16FO_/WKE_>=4\:S;8. @/8&SD4V!$W)"1T<'*,P/#4
M]'.%APX7]P2)KB-<0\4%NWLO3:V1Z&3]O)C-;0&4480B'0"ME#07Z:8^H!)'
M0!",39 @B)+>R\)[9YIHH#!HO29-\NH[;;G%?
M-+U8[XHVN/)W<,W=(Z^&:Y">HQ)<)U2B?S8MX_TC)@RT-U0F.XV%QRR/PV(9
M3<]9U)V-D!?K!Y*BBY]>/;O]HO_3_S+UU;/_ 5!+ 0(4 Q0 ( &^1$E?3
M#NFFMQ, +-U 1 " 0 !B;&-M+3(P,C,P.#(Q+FAT
M;5!+ 0(4 Q0 ( &^1$E<-R